{"nctId":"NCT01270659","briefTitle":"Safety and Efficacy Study of Fentanyl Buccal Tablet Use in the Emergency Department for Isolated Extremity Injury","startDateStruct":{"date":"2011-05"},"conditions":["Pain"],"count":60,"armGroups":[{"label":"Low-FBT","type":"EXPERIMENTAL","interventionNames":["Drug: Fentanyl"]},{"label":"High-FBT","type":"EXPERIMENTAL","interventionNames":["Drug: Fentanyl"]},{"label":"Low control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Oxycodone/acetaminophen"]},{"label":"High control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oxycodone/acetaminophen"]}],"interventions":[{"name":"Fentanyl","otherNames":["Fentora 100 mcg buccal tablet"]},{"name":"Fentanyl","otherNames":["Fentora buccal tablet 200 mcg"]},{"name":"Oxycodone/acetaminophen","otherNames":["Percocet 5/325"]},{"name":"oxycodone/acetaminophen","otherNames":["Percocet 5/325"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* pain sufficient to warrant medication stronger than acetaminophen (Tylenol) or aspirin\n* only if Emergency Department provider approves\n* a negative pregnancy test is required for participation for women of childbearing age\n\nExclusion Criteria:\n\n* If treating provider determines intravenous analgesia is required\n* allergy to acetaminophen or any opiate/opioid, or lansoprazole patients currently taking phenothiazines, CNS depressants (including alcohol), or if they have taken an monoamine oxidase inhibitor (MAOI) or selective serotonin reuptake inhibitor (SSRI) in the past two weeks\n* if patient has already been administered an opioid analgesic for their current injury\n* patients on chronic opioids therapy or a history of opioid abuse\n* breastfeeding mothers\n* patients who plan to drive home after their emergency department visit\n* history of phenylketonuria (due to phenylalanine in the formulation of the lansoprazole solutab)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Median Time to Significant Analgesia (at Least 2 Units Decrease in Pain Level)","description":"Median time (in minutes) to 2 units decrease in pain level after drug administration. Patients were asked to rate their pain at every 5 minutes intervals from 0 to 60 minutes post drug administration. The 10-point verbally administered numeric pain rating scale (NPRS) was used to have patients rate their level of pain on a scale of 0 (no pain) to 10 (worst pain ever).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"15.0","spread":null},{"groupId":"OG003","value":"15.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Nausea Level","description":"Subjects' nausea level was recorded to determine how fentanyl buccal tablet compares to standard therapy in causing nausea. Treatment induced nausea and severity of nausea level was assessed.\n\nNausea was assessed by a 10-point verbally administered scale. Patients rated their degree of nausea on a scale of 0 (no nausea) to 10 (worst nausea).\n\nAt the beginning of the study, literature review found relatively little evidence guiding objective means to rate nausea, but there was some precedent for this approach (Warden C. Prehospital use of ondansetron reduces nausea and episodes of vomiting in adults and children over 12 years old \\[abstract\\]. Prehosp Emerg Care. 2007;11:132).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Any Adverse Events","description":"Occurrence of any adverse event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":6},"commonTop":["Nausea","Pruritis","Drowsy","Headache","Dry mouth"]}}}